Real-world effectiveness and safety of blinatumomab in adults with B-cell precursor acute lymphoblastic leukaemia across 13 European countries - Takeaways - MDSpire

Real-world effectiveness and safety of blinatumomab in adults with B-cell precursor acute lymphoblastic leukaemia across 13 European countries

  • By

  • Sabina Chiaretti

  • Sabine Blum

  • Thibaut Leguay

  • Marie Balsat

  • Cyril Salek

  • Nicola Fracchiolla

  • Alexandros Spyridonidis

  • Anita Rijneveld

  • Cristina Papayannidis

  • Albertina Nunes

  • Anne Christine Wilke

  • Sigrid Machherndl-Spandl

  • Ulla Wartiovaara-Kautto

  • Jessica Choudhry

  • Ravikanth Maraboina

  • Gerhard Zugmaier

  • Noemi Mergen

  • Andreas Ochs

  • Alessandro Rambaldi

  • May 2, 2026

  • 0 min

Share

  • 1

    Blinatumomab is effective for treating MRD+ and R/R Ph− BCP-ALL, with high remission and MRD response rates observed in adult patients.

  • 2

    In the MRD+ group, 81.8% achieved an MRD response, with a median disease-free survival of 31.2 months and a 24-month overall survival rate of 67%.

  • 3

    In the R/R group, 82.0% achieved complete remission, with a median relapse-free survival of 15.9 months and a 24-month overall survival rate of 52%.

  • 4

    Earlier administration of blinatumomab correlated with improved survival outcomes, with longer relapse-free and overall survival in first salvage therapy patients.

  • 5

    Treatment-related adverse events occurred in 68.9% of patients, with the most common being pyrexia, CRS, and headache, highlighting the need for careful monitoring.

Original Source(s)

Real-world effectiveness and safety of blinatumomab in adults with B-cell precursor acute lymphoblastic leukaemia across 13 European countries

  • by Sabina Chiaretti, Sabine Blum, Thibaut Leguay, Marie Balsat, Cyril Salek, Nicola Fracchiolla, Alexandros Spyridonidis, Anita Rijneveld, Cristina Papayannidis, Albertina Nunes, Anne Christine Wilke, Sigrid Machherndl-Spandl, Ulla Wartiovaara-Kautto, Jessica Choudhry, Ravikanth Maraboina, Gerhard Zugmaier, Noemi Mergen, Andreas Ochs, Alessandro Rambaldi

  • May 2, 2026

Related Content

Malignant reninoma with pulmonary metastasis and ATRX mutation treated with olaparib: a case report of specialized treatment

The AACR 2026 Roundup: Why Quantitative Precision Matters

From detection to supporting decisions, Marwan A. Alsarraj reports on precision diagnostics updates from the major cancer conference

Retrospective Characterization of Specialized Palliative Care in Patients With Gliomas

Patients with gliomas face significant challenges in daily life due to rapidly progressing neurological and cognitive symptoms. This study evaluated referral processes for specialized palliative care and interdisciplinary services used by patients with gliomas and their caregivers in Denmark.